U.S. flag

An official website of the United States government, Department of Justice.

NCJRS Virtual Library

The Virtual Library houses over 235,000 criminal justice resources, including all known OJP works.
Click here to search the NCJRS Virtual Library

Prescription Drug Monitoring Program: Nebraska State Profile

NCJ Number
253016
Date Published
October 2018
Length
8 pages
Annotation
Information and data are presented for the Nebraska Prescription Drug Monitoring Program, which is named the Nebraska Health Information Initiative (NeHII), and is administered by the state's Department of Health.
Abstract

The home page website address is provided, and contact information is reported for the NeHII Program Director and Coordinator. Statistics for 2017 cover the state population (1,932,549), DEA registered prescribers (10,898), and DEA registered dispensers (492). NeHII's available reports are listed. NeHII funding for 2018 was from a Harold Rogers grant and a CDC grant. NeHII staff numbers for 2018 are for the following job categories: operational (1), technical (1), analytical (1), and "other" (0). Key dates for the NeHII pertain to enabling legislation (April 2011, February 2016), becoming operational (April 2011), initial user access (April 2011), online access (April 2011), and electronic reporting (April 2011). Sources for statutes and rules relevant to the operation of the NeHII are listed. Reporting frequency for monitored drugs is daily. Monitored prescription drugs are controlled substances in schedules II, III, IV, and V, and NeHII has the authority to monitor other substances and to require the reporting of data on naloxone administering and dispensing. Miscellaneous capabilities and policies are also noted. There is no indication that enrollment or use of NeHII is required for prescribers or dispensers. Law enforcement access to NeHII data on patient prescription drug use requires a subpoena, court order/approval, and a written request. There is a data retention policy, and training in the use of NeHII is required and made available to prescribers and dispensers of monitored drugs.